Efficacy of Mazdutide for Treating PCOS

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Mazdutide

In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly. If well tolerated, the dosage is increased to 4mg once weekly for another 4 weeks. If still well tolerated, the dosage is further increased to 6mg once weekly and maintained for the ensuing 16 weeks.

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER